Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease

NeuroToxicology

Volumn 34, Issue 1, 2013, Pages 25-32

  Kopalli, Spandana Rajendra ^a   Noh, Su Jin ^a   Koppula, Sushruta ^b   Suh, Yoo Hun ^a  

^a Seoul National University   (South Korea)

^b Konkuk University   (South Korea)

Author keywords

6 Hydroxydopamine; Methylparaben; Neurotoxicity; Parkinson's disease; Reactive oxygen species; SH SY5Y cells; Substantia nigra

Indexed keywords

APOMORPHINE; HYDROGEN PEROXIDE; MALONALDEHYDE; METHYL PARABEN; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; BRAIN DAMAGE; BRAIN TISSUE; CELL STRAIN SH SY5Y; CELL VIABILITY; CIRCLING BEHAVIOR; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; MAZE TEST; MOTOR DYSFUNCTION; MOUSE; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PASSIVE AVOIDANCE; PRIORITY JOURNAL; ROTAROD TEST; SUBSTANTIA NIGRA;

ANIMALS; ANTIOXIDANTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CELL LINE, TUMOR; COGNITION; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN PEROXIDE; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; OXIDATIVE STRESS; OXIDOPAMINE; PARABENS; PARKINSONIAN DISORDERS; REACTIVE OXYGEN SPECIES; ROTAROD PERFORMANCE TEST; TYROSINE 3-MONOOXYGENASE;

MUS;

EID: 84870370999     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2012.10.003     Document Type: Article

References (63)

1. Bensadoun J.C., Mirochnitchenko O., Inouye M., Aebischer P., Zurn A.D. Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice. Eur J Neurosci 1998, 10:3231-3236.
2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20:415-455.
3. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001, 65:135-172.
4. Carman L.S., Gage F.H., Shults C.W. Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res 1991, 553:275-283.
5. Carvey P.M., Lin D.H., Faselis C.J., Notermann J.K., Ling Z.D. Loss of striatal DA innervation increases striatal trophic activity directed at DA neurons in culture. Exp Neurol 1996, 140:184-197.
6. Chang R.C., Suen K.C., Ma C.H., Elyaman W., Ng H.K., Hugon J. Involvement of double-stranded RNA-dependent protein kinase and phosphorylation of eukaryotic initiation factor-2alpha in neuronal degeneration. J Neurochem 2002, 83:1215-1225.
7. Chen J.H., Ou H.P., Lin C.Y., Lin F.J., Wu C.R., Chang S.W., et al. Carnosic acid prevents 6-hydroxydopamine-induced cell death in SH-SY5Y cells via mediation of glutathione synthesis. Chem Res Toxicol 2012, 25:1893-1901.
8. Cohen G., Heikkila R.E. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 1974, 249:2447-2452.
9. Da Cunha C., Gevaerd M.S., Vital M.A., Miyoshi E., Andreatini R., Silveira R., et al. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res 2001, 124:9-18.
10. Daniel J.W. Metabolic aspects of antioxidants and preservatives. Xenobiotica 1986, 16:1073-1078.
11. Feng L., Meng H., Wu F., Cheng B., He X., Wang X., et al. Olfactory ensheathing cells conditioned medium prevented apoptosis induced by 6-OHDA in PC12 cells through modulation of intrinsic apoptotic pathways. Int J Dev Neurosci 2008, 26:323-329.
12. Fisher L.J., Young S.J., Tepper J.M., Groves P.M., Gage F.H. Electrophysiological characteristics of cells within mesencephalon suspension grafts. Neuroscience 1991, 40:109-122.
13. Gao M., Zhang W.C., Liu Q.S., Hu J.J., Liu G.T., Du G.H. Pinocembrin prevents glutamate-induced apoptosis in SH-SY5Y neuronal cells via decrease of bax/bcl-2 ratio. Eur J Pharmacol 2008, 591:73-79.
14. Glinka Y., Tipton K.F., Youdim M.B. Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J Neurochem 1996, 66:2004-2010.
15. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978, 14:633-643.
16. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982, 126:131-138.
17. Gupta R.C. Brain regional heterogeneity and toxicological mechanisms of organophosphates and carbamates. Toxicol Mech Methods 2004, 14:103-143.
18. Haddad J.J. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal 2002, 14:879-897.
19. Hara H., Ohta M., Adachi T. Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J Neurosci Res 2006, 84:860-866.
20. Harvey B.H., Carstens M.E., Taljaard J.J. Central effects of the preservative, methylparaben, in vivo activation of cAMP-specific phosphodiesterase and reduction of cortical cAMP. Biochem Pharmacol 1992, 44:1053-1057.
21. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995, 64:919-924.
22. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
23. Iancu R., Mohapel P., Brundin P., Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005, 162:1-10.
24. Inanami O., Watanabe Y., Syuto B., Nakano M., Tsuji M., Kuwabara M. Oral administration of (-)catechin protects against ischemia-reperfusion-induced neuronal death in the gerbil. Free Radical Res 1998, 29:359-365.
25. Jang J.H., Surh Y.J. Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells. Mutat Res 2001, 496:181-190.
26. Jakel R.J., Townsend J.A., Kraft A.D., Johnson J.A. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res 2007, 1144:192-201.
27. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003, 53(Suppl. 3):S26-S36. discussion S-8.
28. Jones D.T., Morrison J.L., Richardson A.P. p-Hydroxybenzoic acid esters as preservatives. III. The physiological disposition of p-hydroxybenzoic acid and its esters. J Am Pharm Assoc: Science Edition 1956, 45:265-273.
29. Kelsey N.A., Wilkins H.M., Linseman D.A. Nutraceutical antioxidants as novel neuroprotective agents. Molecules 2010, 15:7792-7814.
30. Koo J.W.P.C., Choi S.H., Kim N.J., Kim H.S., Choe J.C., Suh Y.H. Postnatal environment can counteract prenatal effects on cognitive ability, cell proliferation, and synaptic protein expression. FASEB J 2003, 17:1556-1558.
31. Kumar R., Agarwal A.K., Seth P.K. Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 1995, 64:1703-1707.
32. Kowaltowski A.J., Vercesi A.E., Fiskum G. Bcl-2 prevents mitochondrial permeability transition and cytochrome c release via maintenance of reduced pyridine nucleotides. Cell Death Differ 2000, 7:903-910.
33. Levkovitch-Verbin H., Harris-Cerruti C., Groner Y., Wheeler L.A., Schwartz M., Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 2000, 41:4169-4174.
34. Mandel S., Grunblatt E., Riederer P., Gerlach M., Levites Y., Youdim M.B. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 2003, 17:729-762.
35. Matsuzawa A., Ichijo H. Stress-responsive protein kinases in redox-regulated apoptosis signaling. Antioxid Redox Signal 2005, 7:472-481.
36. McDonnell T.J., Chang S.W., Westcott J.Y., Voelkel N.F. Role of oxidants, eicosanoids, and neutrophils in amphotericin B lung injury in rats. J Appl Physiol 1988, 65:2195-2206.
37. Rascol O., Brooks D., Melamed E., Oertel W., Poewe W., et al. A comparative randomised study of rasagiline versus placebo or entacapone as adjuncts to levodopa in Parkinson's disease patients with motor fluctuations (the LARGO study). Eur J Neurol 2003, 10:234-244.
38. Rogers K.L., Grice I.D., Griffiths L.R. Modulation of in vitro platelet 5-HT release by species of Erythrina and Cymbopogon. Life Sci 2001, 69:1817-1829.
39. Rozas G., Guerra M.J., Labandeira-Garcia J.L. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 1997, 2:75-84.
40. Sarter M., Bodewitz G., Stephens D.N. Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology (Berl) 1988, 94:491-495.
41. Satoh T., Enokido Y., Aoshima H., Uchiyama Y., Hatanaka H. Changes in mitochondrial membrane potential during oxidative stress-induced apoptosis in PC12 cells. J Neurosci Res 1997, 50:413-420.
42. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004, 318:215-224.
43. Shen Z., Wang G., Lin S.Z. Two-way shuttlebox avoidance conditioning and brain NADH in rats. Physiol Behav 1990, 48:515-517.
44. Smolinske S.C. Parabens. Handbook of food, drug, and cosmetic excipients 1992, CRC Press, Boca Raton, FL, p. 251-8.
45. Song B.L., Li H.Y., Peng D.R. In-vitro spermicidal activity of parabens against human spermatozoa. Contraception 1989, 39:331-336.
46. Soni M.G., Taylor S.L., Greenberg N.A., Burdock G.A. Evaluation of the health aspects of methyl paraben: a review of the published literature. Food Chem Toxicol 2002, 40:1335-1373.
47. Soto-Otero R., Mendez-Alvarez E., Hermida-Ameijeiras A., Munoz-Patino A.M., Labandeira-Garcia J.L. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 2000, 74:1605-1612.
48. Storch A., Burkhardt K., Ludolph A.C., Schwarz J. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J Neurochem 2000, 75:2259-2269.
49. Takahashi T., Deng Y., Maruyama W., Dostert P., Kawai M., Naoi M. Uptake of a neurotoxin-candidate, (R)-1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline into human dopaminergic neuroblastoma SH-SY5Y cells by dopamine transport system. J Neural Transm Gen Sect 1994, 98:107-118.
50. Tiffany-Castiglioni E., Saneto R.P., Proctor P.H., Perez-Polo J.R. Participation of active oxygen species in 6-hydroxydopamine toxicity to a human neuroblastoma cell line. Biochem Pharmacol 1982, 31:181-188.
51. TNO Volatile Compounds in Food, Database Software 2000, Boelens Aroma Chemical Information Service, The Netherlands.
52. Tobón-Velasco J.C., Vázquez-Victorio G., Macías-Silva M., Cuevas E., Ali S.F., Maldonado P.D., et al. S-Allyl cysteine protects against 6-hydroxydopamine-induced neurotoxicity in the rat striatum: Involvement of Nrf2 transcription factor activation and modulation of signaling kinase cascades. Free Radic Biol Med 2012, 53:1024-1040.
53. von Coelln R., Kugler S., Bahr M., Weller M., Dichgans J., Schulz J.B. Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. J Neurochem 2001, 77:263-273.
54. Wang X.J., Xu J.X. Salvianic acid A protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity. Neurosci Res 2005, 51:129-138.
55. Whishaw I.Q.L.K., Whishaw P.A., Gorny B., Metz G.A. Distinct forelimb and hind limb stepping impairments in unilateral dopamine-depleted rats: use of the rotorod as a method for the qualitative analysis of skilled walking. J Neurosci Methods 2003, 126:13-23.
56. Willis G.L., Robertson A.D. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23. Pharmacol Biochem Behav 2005, 80:9-26.
57. Xiao X.Q., Zhang H.Y., Tang X.C., Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 2002, 67:30-36.
58. Xue S., Jia L., Jia J. Hypoxia and reoxygenation increased BACE1 mRNA and protein levels in human neuroblastoma SH-SY5Y cells. Neurosci Lett 2006, 405:231-235.
59. Yoneda T., Hiramatsu M., Sakamoto M., Togasaki K., Komatsu M., Yamaguchi K. Antioxidant effects of " beta catechin" Biochem Mol Biol Int 1995, 35:995-1008.
60. Zhang L., Yu H., Sun Y., Lin X., Chen B., Tan C., et al. Protective effects of salidroside on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Eur J Pharmacol 2007, 564:18-25.
61. Zhang Z., Cui W., Li G., Yuan S., Xu D., Hoi M.P., et al. Baicalein protects against 6-OHDA-induced neurotoxicity through activation of Keap1/Nrf2/HO-1 and involving PKCα and PI3K/AKT signaling pathways. J Agric Food Chem 2012, 60:8171-8182.
62. 2 in mitochondria. J Biol Chem 2003, 278:2356-2360.
63. Zheng L., Roberg K., Jerhammar F., Marcusson J., Terman A. Autophagy of amyloid beta-protein in differentiated neuroblastoma cells exposed to oxidative stress. Neurosci Lett 2006, 394:184-189.